Blog

Excitement Grows for Immunotherapy in Lung Cancer – Curetoday.com


Curetoday.com

Excitement Grows for Immunotherapy in Lung Cancer
Curetoday.com
Can you discuss your presentation on checkpoint inhibitors in NSCLC? I was asked to speak on first- and second-line immunotherapy in lung cancer, as well as third-line and beyond. I reviewed the various trials that led to the FDA approval of first-line

2017-10-14 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.